APA

Massard C., Azaro A., Soria J., Lassen U., Le Tourneau C., Sarker D., Smith C., Ohnmacht U., Oakley G., Patel B. K. R., Yuen E. S. M., Benhadji K. A. & Rodon J. (20191223). First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer. : Annals of oncology : official journal of the European Society for Medical Oncology.

Chicago

Massard C, Azaro A, Soria J-C, Lassen U, Le Tourneau C, Sarker D, Smith C, Ohnmacht U, Oakley G, Patel B K R, Yuen E S M, Benhadji K A and Rodon J. 20191223. First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer. : Annals of oncology : official journal of the European Society for Medical Oncology.

Harvard

Massard C., Azaro A., Soria J., Lassen U., Le Tourneau C., Sarker D., Smith C., Ohnmacht U., Oakley G., Patel B. K. R., Yuen E. S. M., Benhadji K. A. and Rodon J. (20191223). First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer. : Annals of oncology : official journal of the European Society for Medical Oncology.

MLA

Massard C, Azaro A, Soria J-C, Lassen U, Le Tourneau C, Sarker D, Smith C, Ohnmacht U, Oakley G, Patel B K R, Yuen E S M, Benhadji K A and Rodon J. First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer. : Annals of oncology : official journal of the European Society for Medical Oncology. 20191223.